REGN · News · 20261112N
Product / Drug Pipeline Progress
REGENERON PHARMACEUTICALS, INC. · 2026-11-12 · Importance 31 · Surprise 42
Regeneron reported first-in-human results for CIDEBsiRNA, an investigational liver-targeted siRNA for metabolic dysfunction-associated steatotic liver disease (MASLD). A single dose reduced liver fat by 58%–80%, with reductions sustained through 36 weeks; 62% of treated participants achieved normal liver fat levels, compared with none in the placebo group. The study also showed improvements in liver injury markers, and the results were presented at AASLD and published in The New England Journal of Medicine.
Key facts
- Regeneron planned a potentially pivotal Phase 3 trial of baloncibart for the first half of 2027. source
- A single dose of Regeneron's baloncibart reduced the exaggerated heart-rate response to standing and improved orthostatic symptoms through four weeks; biomarker changes were consistent with plasma-volume expansion, the intended effect of NPR1 blockade. source
- Regeneron's CIDEBsiRNA is a liver-targeted siRNA candidate for MASLD; early human study results showed sustained normalization of liver fat and improvement in liver injury markers in treated participants. source
- Regeneron reported early-stage human trial data for CIDEBsiRNA showing dose-dependent liver fat reductions and sustained improvements in liver injury markers in patients with MASLD. source